M.D. Anderson Cancer Center
The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.
Primary Objective: To evaluate 1-year overall survival (OS) following CBT with intermediate dose intensity conditioning for patients in need of a second allogeneic stem cell transplantation. Secondary Objectives: Speed and success of neutrophil and platelet engraftment. Incidences of graft failure. • Incidence of day 100 grade II-IV and III-IV aGVHD and day 180 grades II-IV and III-IV aGVHD. Incidence of 1-year, 2-year, and 3-year cGVHD. Incidence of TRM (100 days, 6 months, 1 and 2 years). The probabilities of relapse, OS, PFS, and GRFS at 1 year, 2, and 3 years as listed in the second…
Inclusion Criteria: 1. Patient aged 0-60 y/o at the time of consent. Adult is defined as patients 18 years of age or older at the time of consent. 2. Patient must have relapsed \>100 days since first transplant. 3. Diagnosis and Disease Status: a. Acute myelogenous leukemia (AML): i. Patients in morphologic remission (\<5% blasts) at the time of transplant, with or without persistent cytogenetic, flow cytometric, or molecular aberrations, or those with hypocellular marrows at time of transplant, are eligible. b. Acute lymphoblastic leukemia (ALL): i. Patients in morphologic remission with…
Given as standard of care treatment through IV infusion
Given as standard of care treatment through IV infusion
Given as standard of care treatment through IV infusion
Given as standard of care treatment through IV infusion
Given as standard of care treatment through IV infusion
Arctuva estimate
Verify or correct the compensation shown for this listing.